<address id="hp999"><nobr id="hp999"><meter id="hp999"></meter></nobr></address>
    <address id="hp999"><address id="hp999"></address></address>
    <noframes id="hp999">

    <address id="hp999"></address> <noframes id="hp999"><address id="hp999"></address>

    <noframes id="hp999"><form id="hp999"><nobr id="hp999"></nobr></form>
      <noframes id="hp999"><address id="hp999"><nobr id="hp999"></nobr></address>

      <form id="hp999"></form>
      <form id="hp999"></form>

        相關文章

        Related articles

        產品中心/ PRODUCTS

        我的位置:首頁  >  產品中心  >    >  動物活體成像設備  >  腫瘤測量儀

        腫瘤測量儀

        • 更新時間:2023-08-21
        • 訪  問  量:263

        簡要描述:動物腫瘤測量儀,非常適合對大鼠小鼠等動物的皮下腫瘤進行快速測量、分析,精確測量動物腫瘤并對腫瘤信息存檔與跟蹤

        在線咨詢

        聯系電話:021-54377179

        產品詳情

        動物腫瘤測量儀,非常適合對大鼠小鼠等動物的皮下腫瘤進行快速測量、分析,精確測量動物腫瘤并對腫瘤信息存檔與跟蹤。


        主要技術參數: 

        · 測量范圍:0-25mm腫瘤尺寸:20*20*20mm
        · 3D測量精確度:<0.3mm
        · 圖像捕捉時間:0.1s
        · 接口:USB 2.0
        · 相機:1600*1200 像素(2MP)
        · 工作距離:50mm


        動物腫瘤測量分析儀的主要特點: 
        · 手持式成像裝置,實現立體成像;
        · 適合測量不同尺寸的腫瘤;
        · 方便使用:觸屏式電腦,操作方便;
        · 內置軟件,自動計算腫瘤尺寸,跟蹤整個實驗進展。 
          

        · 快速,高效,保證了高通量和可靠測量;
        · 全自動測量跟蹤系統;
        · 實時數據分析與處理。 


             
          
         


        部分用戶: 

        Hunter College, CUNY

        Vanderbilt University Medical Center

        Hainan Medical University

        Howard Hughes Medical Institute

        Memorial Sloan Kettering Cancer Center

        Cancer Center Amsterdam

        GlaxoSmithKline

        Imec

        K.U.Leuven

        Neuro-Electronics Research Flanders

        Pepric

        PharmaVize

        reMYND

        University Ghent

        SEPS Pharma

        Vlaams Instituut voor Biotechnologie

        University Antwerp

        ThromboGenics

        Janssen Pharmaceutica

        City University of Hong Kong


        參考文獻:

        1.Adams EJ, Karthaus WR, Hoover E, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408-412. doi:10.1038/s41586-019-1318-9.
        2.Zhang Z, Zhou C, Li X, et al. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell. 2020;37(4):584-598.e11. doi:10.1016/j.ccell.2020.03.001.
        3.Santich BH, Park JA, Tran H, et al. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Sci Transl Med. 2020;12(534):eaax1315. doi:10.1126/scitranslmed.aax1315.
        4.Park JA, Xu H, Cheung, I, et al. Abstract B38: Tetravalent bispecific antibodies specific for HER2 and disialoganglioside GD2 to engage polyclonal T cells for osteosarcoma therapy. Cancer Res. 2018;78(19),B38.doi:10.1158/1538-7445.PEDCA17-B38.
        5.Wu CF, Wu CY, Lin CF, et al. The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. Biomed Pharmacother. 2022;151:113128. doi:10.1016/j.biopha.2022.113128.
        6.Wang L, Hoseini SS, Xu H, et al. Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency. Cancer Immunol Res. 2019;7(12):2013-2024. doi:10.1158/2326-6066.CIR-19-0121.
        7.Grochowska A, Statkiewicz M, Kulecka M, et al. Evidence supporting the oncogenic role of BAZ1B in colorectal cancer. Am J Cancer Res. 2022;12(10):4751-4763. 
        8.Hoseini SS, Vadlamudi M, Espinosa-Cotton M, et al. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. J Immunother Cancer. 2021;9(5):e002509. doi:10.1136/jitc-2021-002509.
        9.Beguin E, Gray MD, Logan KA, et al. Magnetic microbubble mediated chemo-sonodynamic therapy using a combined magnetic-acoustic device. J Control Release. 2020;317:23-33. doi:10.1016/j.jconrel.2019.11.013.
        10.Mao N, Gao D, Hu W, et al. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes. Mol Cancer Ther. 2019;18(9):1577-1586. doi:10.1158/1535-7163.MCT-18-1386.
        11.Wu Z, Guo HF, Xu H, et al. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers. Mol Cancer Ther. 2018;17(10):2164-2175. doi:10.1158/1535-7163.MCT-18-0026.
        12.Poty S, Mandleywala K, O'Neill E, et al. 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics. 2020;10(13):5802-5814. doi:10.7150/thno.44772.
        13.Hoseini SS, Guo H, Wu Z, et al. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Adv. 2018;2(11):1250-1258. doi:10.1182/bloodadvances.2017014373.
        14.Zhang Z, Karthaus WR, Lee YS, et al. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020;38(2):279-296.e9. doi:10.1016/j.ccell.2020.06.005.
        15.Poty S, Carter LM, Mandleywala K, et al. Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2019;25(2):868-880. doi:10.1158/1078-0432.CCR-18-1650.




            

            

            :,

                 

            :

            yuyanbio

            :yuyanbio

            

        在線咨詢

        留言框

        • 產品:

        • 您的單位:

        • 您的姓名:

        • 聯系電話:

        • 常用郵箱:

        • 省份:

        • 詳細地址:

        • 補充說明:

        • 驗證碼:

          請輸入計算結果(填寫阿拉伯數字),如:三加四=7
        上海玉研科學儀器有限公司
        地址:上海市閔行區興梅路485號眾欣大廈506室
        郵箱:sales@yuyanbio.com
        傳真:021-35183767
        掃一掃關注我們
        SCAN
        亚洲AⅤ永久无码精品三区在线_国产三级精品三级男人的天堂_人妻被按摩师玩弄到潮喷_欧美成a人片在线观看久

        <address id="hp999"><nobr id="hp999"><meter id="hp999"></meter></nobr></address>
          <address id="hp999"><address id="hp999"></address></address>
          <noframes id="hp999">

          <address id="hp999"></address> <noframes id="hp999"><address id="hp999"></address>

          <noframes id="hp999"><form id="hp999"><nobr id="hp999"></nobr></form>
            <noframes id="hp999"><address id="hp999"><nobr id="hp999"></nobr></address>

            <form id="hp999"></form>
            <form id="hp999"></form>